Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | THPO | P40225 | 2/20 | 0.32 |
| ▸ | PPM1B | O75688 | 2/20 | 0.32 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.32 |
| ▸ | TFPI2 | P48307 | 2/20 | 0.32 |
| ▸ | PPP5C | P53041 | 2/20 | 0.32 |
| ▸ | PPP1CA | P62136 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 2/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3381973 | 1.00 | TP53 (0.32) | TP53CYP3A4MAPK1LMNASMN1; SMN2 | |
| SCHEMBL13349763 | 1.00 | TP53 (0.32) | TP53CYP3A4MAPK1LMNASMN1; SMN2 | |
| SCHEMBL2698215 | 0.86 | KDM4E (0.37) | TP53LMNASMN1; SMN2RAB9ANFKB1 | |
| SCHEMBL12172563 | 0.75 | TP53 (0.48) | TP53CYP3A4MAPK1LMNASMN1; SMN2 | |
| SCHEMBL18951250 | 0.75 | TP53 (0.48) | TP53CYP3A4MAPK1LMNASMN1; SMN2 | |
| SCHEMBL19557679 | 0.75 | — | — | |
| SCHEMBL18785025 | 0.75 | TP53 (0.48) | TP53CYP3A4MAPK1LMNASMN1; SMN2 | |
| SCHEMBL10303469 | 0.75 | CACNA1B (0.31) | — | |
| SCHEMBL5708679 | 0.73 | — | — | |
| SCHEMBL16134330 | 0.73 | KDM4E (0.33) | TP53LMNASMN1; SMN2RAB9ANFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118702614-A | Preparation method of chiral azabicyclo ester compound | 江西迪赛诺制药有限公司 | 2024-09-27 | — | — | CN | disclosed |
| WO-2021222353-A1 | MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9695149-B2 | 1,2,6-substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-04 | — | — | US | disclosed |
| US-9682971-B2 | 1,2,5-Substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-9682972-B2 | 1,2,5-substituted benzimidazoles as flap modulators | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-20 | — | — | US | disclosed |
| US-20160108028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-21 | — | — | US | disclosed |
| US-9265770-B2 | 1,2,5-substituted benzimidazoles as FLAP modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-23 | — | — | US | disclosed |
| US-20160046600-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | CHAI WENYING (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160039790-A1 | 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-20150246052-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-03 | — | — | US | disclosed |
| US-20090240063-A1 | Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... | MERCK SHARP & DOHME CORP. | 2009-09-24 | — | — | US | disclosed |
| US-7569705-B2 | Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates for salts thereof | SCHERING CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| US-7569705-B2 | Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates for salts thereof | SCHERING CORPORATION (US) | 2009-08-04 | — | — | US | disclosed |
| WO-2009073380-A1 | DEHYDROHALOGENATION PROCESS FOR THE PREPARATION OF INTERMEDIATES USEFUL IN PROVIDING 6,6-DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS | SCHERING CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20080114179-A1 | Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates for salts thereof | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-20080114179-A1 | Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates for salts thereof | MERCK SHARP & DOHME CORP. | 2008-05-15 | — | — | US | disclosed |
| US-7309717-B2 | Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| US-7309717-B2 | Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates or salts thereof | SCHERING CORPORATION (US) | 2007-12-18 | — | — | US | disclosed |
| WO-2007075790-A1 | PROCESS FOR THE PREPARATION OF 6, 6-DIMETHYL-3-AZABICYCLO-[3.1.0]-HEXANE COMPOUNDS AND ENANTIOMERIC SALTS THEREOF | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2004016260-A1 | THERAPEUTIC USE OF FUSED BICYCLIC OR TRICYCLIC AMINO ACIDS | PFIZER LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246052-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | TP53 257/4885CYP3A4 5/4885MAPK1 4196/4885 |
| US-20160039790-A1 | 1,2,6-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, F12 | TP53 476/4885CYP3A4 9/4885MAPK1 4083/4885 |
| US-20080114179-A1 | Process and intermediates for the preparation of (1R,2S,5S)-6,6-dimethyl-3-azabicyclo[3,1,0]hexane-2-carboxylates for salts thereof | AZI2, MED1, ADH1C | TP53 3240/4885CYP3A4 352/4885MAPK1 763/4885 |
| US-20160046600-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | TP53 257/4885CYP3A4 5/4885MAPK1 4196/4885 |
| US-20160108028-A1 | 1,2,5-SUBSTITUTED BENZIMIDAZOLES AS FLAP MODULATORS | FEN1, FOXM1, CYP3A5 | TP53 257/4885CYP3A4 5/4885MAPK1 4196/4885 |
| US-20090240063-A1 | Process For The Preparation Of 6,6-Dimethyl-3-Azabicyclo-[3.1.0]-Hexane Compounds ... | TMT1A, HDHD5, TET1 | TP53 2998/4885CYP3A4 1367/4885MAPK1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.